BI-2865 Mechanism of Action: KRAS Inhibition in Cancer Cell Research

BI-2865 MOA:Targeting KRAS/MAPK Pathway for Pan-KRAS Targeted Therapy for Solid Tumors

🎯 check BI-2865 product page

BI-2865 is a potent KRAS/P-gp inhibitor. It affects ERK/AKT signaling pathways, by reducing KRAS-GTP, inhibiting MDR and growth.

Primary Applications and Mechanism of Action